Presenting Companies: Diagnostic Technologies Ltd.
Core Business / Technology
Diagnostic Technologies LTD (DTL) develops and produces devices for early detection of high risk pregnancy based on genomics and proteomics. Incubated in Technion - Israel Institute of Technology, the company uses new placenta genes and proteins to detect abnormal pregnancy development related to pre-eclampsia, IUGR and preterm delivery.
Main Markets / Applications
Every 10th baby is born prematurely; every 7th woman is at high-risk for delivering premature babies, and pre-eclampsia affects 5% of all pregnant women. US healthcare expenditures to treat the threatening complications of life loss, blindness, and motor & mental disorders of premature newborns, and of pregnancy hypertension along with kidney, liver & cardiovascular malfunctioning that can turn into eclampsia, brain convulsion & death amount to $22-33 billon annually.
DTL’s lead marker of pregnancy complications is Placental Protein 13 (PP-13) that was incorporated into ELISA kit to predict the risk before complications develop for assuring a safer pregnancy, and a full term baby. The product uses a blood sample taken with the routine pregnancy blood tests, and effectively detects 1st & 2nd trimester abnormal PP-13 levels. The kit is easy to use, reliable, and sensitive. The in-vitro procedure needs no special equipment and meets all quality standards.
Early detection enables the adoption of protective measures before complications develop - behavioral change, bed rest, vitamins and anti-oxidant supplements, frequent blood pressure monitoring, suitable medication and follow up doctor care, that can save at least $4-10 billion annually.
Main Products Marketed or Under Development
An ELISA kit to detect pregnancy complications by measuring serum level of Placental Protein 13 (PP-13) to predict the risk before complications develop for assuring a safer pregnancy, and a full term baby. The product uses a blood sample taken with the routine pregnancy blood tests, and effectively detects 1st & 2nd trimester abnormal PP-13 levels. The kit is easy to use, reliable, and sensitive. The in-vitro procedure needs no special equipment and meets all quality standards.
A DNA based kit to verify the genetic nature of pregnancy complications A vagina/urine RAPID test to predict amniotic fluid leak.
Uniqueness / Advantage over Existing Products
Today there is no product for detecting high-risk pregnancy complications. The major barriers in the market are regulatory approvals, reimbursement, and product acceptance by leading physicians and by the patients. Early detection enables prevention; low cost ($55/patient in the U.S. final customer cost); user friendly and standard format testing and use blood drawn in routine pregnancy testing. There is no need for a special physician visit.
Management
1) Mr. Giora Meyuhas, Chairman of the Board
2) Dr. Hamutal Meiri, CEO
3) Dr. Yair Gibor, VP Regulatory & Medical Affairs
4) Mr. Hanan Hershkovitch, CFO
Website
none
| 
